Bharat Biotech’s COVID-19 vaccine Covaxin neutralises multiple variants of Coronavirus and works in a better way against the double mutant strain, according to Indian Council of Medical Research (ICMR).
“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR said in a tweet.
Cavaxin received Emergency Use Authorizations (EUA) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process.
In the tweet, ICMR said “ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant). B.1.1.28 (Brazil variant) and B.1.351 (South Africa variant).”
Further the Institute said “ICMR-NIV has demonstrated the neutralisation potential of Cavaxin against the UK variant and Brazil variant. ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries. Covaxin has been found to effectively neutralise the double mutant strain as well.” it said.
